GRAIL (NASDAQ:GRAL) Shares Gap Down – Time to Sell?

GRAIL, Inc. (NASDAQ:GRAL) gapped down prior to trading on Tuesday . The stock had previously closed at $59.81, but opened at $57.12. GRAIL shares last traded at $59.7410, with a volume of 68,353 shares trading hands.

Trending Headlines about GRAIL

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: No meaningful positive catalysts were reported in the latest news flow for GRAIL.
• Neutral Sentiment: Multiple law firms, including Rosen, Faruqi & Faruqi, Robbins Geller, and others, issued reminders about the August 4 deadline to seek lead-plaintiff status in an already filed securities class action. Article Title
• Neutral Sentiment: The class action covers investors who bought GRAIL stock between May 13, 2025 and February 19, 2026, with allegations centered on alleged misrepresentations about whether the NHS-Galleri trial could meet its endpoint of reducing late-stage cancers. Article Title
• Negative Sentiment: The lawsuit alleges GRAIL misled investors about the NHS-Galleri trial, which reportedly preceded a sharp stock decline; that raises the risk of damages, legal expenses, and further investor caution. Article Title

Analyst Ratings Changes

A number of analysts recently weighed in on GRAL shares. Mizuho started coverage on shares of GRAIL in a research note on Friday, April 10th. They issued a “neutral” rating and a $58.00 target price on the stock. Wall Street Zen raised shares of GRAIL from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Wolfe Research started coverage on shares of GRAIL in a research note on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. Robert W. Baird set a $70.00 target price on shares of GRAIL in a research note on Wednesday, May 6th. Finally, Canaccord Genuity Group lowered their target price on shares of GRAIL from $105.00 to $80.00 and set a “buy” rating on the stock in a research note on Friday, February 20th. Four research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, GRAIL currently has an average rating of “Hold” and a consensus target price of $67.00.

GRAIL Price Performance

The business’s 50 day moving average price is $58.33 and its 200-day moving average price is $73.96. The company has a market cap of $2.58 billion, a P/E ratio of -5.80 and a beta of 3.15.

GRAIL (NASDAQ:GRAL) last posted its earnings results on Tuesday, May 5th. The company reported ($2.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.76) by $0.47. GRAIL had a negative net margin of 253.22% and a negative return on equity of 16.42%. The company had revenue of $40.79 million during the quarter, compared to analysts’ expectations of $39.16 million. As a group, research analysts forecast that GRAIL, Inc. will post -10.99 EPS for the current year.

Insider Activity

In other news, CEO Robert P. Ragusa sold 123,502 shares of GRAIL stock in a transaction that occurred on Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total value of $6,165,219.84. Following the completion of the transaction, the chief executive officer owned 518,582 shares in the company, valued at approximately $25,887,613.44. The trade was a 19.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Aaron Freidin sold 45,806 shares of GRAIL stock in a transaction that occurred on Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total transaction of $2,286,635.52. Following the completion of the transaction, the chief financial officer owned 260,669 shares of the company’s stock, valued at $13,012,596.48. This trade represents a 14.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 232,464 shares of company stock worth $11,621,242. 1.83% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Fifth Third Bancorp grew its stake in shares of GRAIL by 15,733.3% during the first quarter. Fifth Third Bancorp now owns 475 shares of the company’s stock valued at $25,000 after purchasing an additional 472 shares during the last quarter. N.E.W. Advisory Services LLC acquired a new stake in GRAIL during the 4th quarter worth $26,000. Comerica Bank grew its holdings in GRAIL by 59.2% during the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock worth $27,000 after acquiring an additional 173 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in GRAIL during the 4th quarter worth $28,000. Finally, Geneos Wealth Management Inc. grew its holdings in GRAIL by 160.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 585 shares of the company’s stock worth $30,000 after acquiring an additional 360 shares during the period.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.